What is it about?
Plumbagin is a plant-derived compound with chemotherapeutic activity. This article shows that plumbagin causes prostate tumors to shrink when given together with androgen deprivation therapy, which is currently the standard treatment for prostate cancer. In animals, Plumbagin improves the efficacy of Lupron, Firmagon, Zitiga, Orteronel and Avodart. It does not improve the efficacy of Casodex or Xtandi.
Featured Image
Why is it important?
A new oral formulation of Plumbagin (PCUR-101) is undergoing phase I clinical trial for the treatment of prostate cancer. If phase I is successful and moves to phase II, results described here will help chose the best modalities to test in patients.
Perspectives
The development of Plumbagin into a clinical drug was a tremendous effort from a very small team. It is a great satisfaction to see it go into clinical trial. Our hope is that it will eventually increase survival in cancer patients.
veronique baron
Vaccine Research Institute of San Diego
Read the Original
This page is a summary of: Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study, The Prostate, October 2017, Wiley,
DOI: 10.1002/pros.23428.
You can read the full text:
Contributors
The following have contributed to this page
